The Halyard Health Inc. (HYH) Rating Decreased to Hold at The Zacks Investment Research

The Halyard Health Inc. (HYH) Rating Decreased to Hold at The Zacks Investment Research

Zacks Investment Research downgraded shares of Halyard Health Inc. (NYSE:HYH) from a buy rating to a hold rating in a report published on Tuesday morning.

According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “

Other analysts also recently issued reports about the company. Stifel Nicolaus upped their price objective on Halyard Health from $37.00 to $38.00 and gave the company a buy rating in a research note on Thursday, August 4th. Deutsche Bank AG upped their price objective on Halyard Health from $36.00 to $41.00 and gave the company a buy rating in a research note on Wednesday, August 10th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $38.00.

Shares of Halyard Health (NYSE:HYH) opened at 37.09 on Tuesday. The stock has a 50 day moving average price of $34.33 and a 200-day moving average price of $33.82. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of 39.50 and a beta of 1.77. Halyard Health has a 52 week low of $22.76 and a 52 week high of $37.31.

Halyard Health (NYSE:HYH) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.39 by $0.09. The firm earned $398 million during the quarter, compared to the consensus estimate of $387.64 million. Halyard Health had a return on equity of 8.63% and a net margin of 2.80%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.52 EPS. On average, analysts anticipate that Halyard Health will post $1.91 EPS for the current year.

Institutional investors have recently modified their holdings of the company. Commonwealth Equity Services Inc increased its position in shares of Halyard Health by 0.4% in the second quarter. Commonwealth Equity Services Inc now owns 11,342 shares of the company’s stock worth $369,000 after buying an additional 48 shares during the period. IFP Advisors Inc increased its position in shares of Halyard Health by 1.9% in the second quarter. IFP Advisors Inc now owns 3,141 shares of the company’s stock worth $102,000 after buying an additional 58 shares during the period. ProShare Advisors LLC increased its position in shares of Halyard Health by 0.6% in the second quarter. ProShare Advisors LLC now owns 11,357 shares of the company’s stock worth $369,000 after buying an additional 70 shares during the period. State Treasurer State of Michigan increased its position in shares of Halyard Health by 0.5% in the third quarter. State Treasurer State of Michigan now owns 18,820 shares of the company’s stock worth $652,000 after buying an additional 100 shares during the period. Finally, D.A. Davidson & CO. increased its position in shares of Halyard Health by 2.9% in the third quarter. D.A. Davidson & CO. now owns 6,127 shares of the company’s stock worth $211,000 after buying an additional 171 shares during the period. 85.90% of the stock is owned by institutional investors and hedge funds.

Halyard Health Company Profile

Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.

Related posts

Leave a Comment